Steven Kurtzman, MD
Radiation Oncology · Garfield Heights, OHNPI 1114918851
Payments from drug & device makers
Across 139 payments — averaging $5991.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Isoray, Inc$827K
- Boston Scientific$2K
- Theragenics Corporation$1K
- Palette Life Sciences, Inc.$1K
- Teleflex LLC$191
- Bioprotect Medical, Inc.$187
- plus $475 from 8 others
What the payments were for
- Consulting fees$824,98599%
- Speaking & faculty fees$8300%
- Travel & lodging$3820%
- Food & beverage$6,6521%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Isoray, Inc | 60 | $827,416 |
| Boston Scientific | 37 | $2,132 |
| Theragenics Corporation | 15 | $1,305 |
| Palette Life Sciences, Inc. | 12 | $1,144 |
| Teleflex LLC | 1 | $191 |
| Bioprotect Medical, Inc. | 4 | $187 |
| GT Medical Technologies, Inc | 2 | $132 |
| Amgen | 1 | $116 |
| Varian Medical Systems, Inc. | 1 | $63 |
| Qfix | 1 | $58 |
| AbbVie | 2 | $42 |
| Siemens Medical Solutions USA, Inc. | 1 | $22 |
| Telix Pharmaceuticals | 1 | $22 |
| Tolmar, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Brachytherapy Source$606,446
- SpaceOAR VUE System - 10mL$591
- GENERAL - THERAPIES$223
- Barrigel$191
- Otezla$116
- SpaceOAR System$108
- GENERAL ONCOLOGY$104
How this compares
$832,849 in reported general payments places this provider in the 95th percentile of 255 radiation oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 95 | $1,164 |
| Pregabalin | 15 | $345 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 114 | $252 |
| Methylprednisolone | 21 | $92 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Garfield Heights
- Ankit AgarwalGarfield Heights$18K
- John ShumwayGarfield Heights$3K
- Shlomo KoyfmanCleveland$2.4M
- Arnab ChakravartiColumbus$1.4M
- Angela Yuanyuan JiaCleveland$1M
- Daniel SprattCleveland$834K
- Jeremy BrownsteinColumbus$522K
- Sasha BeyerColumbus$504K
- John BrenemanCincinnati$503K
- Joshua PalmerColumbus$453K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.